Screener
Arbutus Biopharma Corporation ABUS Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of contingent consideration | 209 | 299 |
| Restructuring costs | — | 12,373 |
| Total operating expenses | 10,218 | 27,463 |
| Income (loss) from operations | 168,908 | (25,699) |
| Other income | ||
| Interest income | 815 | 1,197 |
| Interest expense | (17) | (28) |
| Foreign exchange (loss) gain | (11) | 4 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's operating income?
- Arbutus Biopharma Corporation (ABUS) reported operating income of $168.91M in Q1 2026.
- How has Arbutus Biopharma Corporation's operating income changed year-over-year?
- Arbutus Biopharma Corporation's operating income increased by 757.3% year-over-year, from -$25.7M to $168.91M.
- What is the long-term trend for Arbutus Biopharma Corporation's operating income?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's operating income has grown at a -15.1% compound annual growth rate (CAGR), from -$73.52M to -$38.16M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Arbutus Biopharma Corporation's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude